
Oncology NEWS International
- Oncology NEWS International Vol 15 No 5
- Volume 15
- Issue 5
Novartis Seeks Approval for Gleevec in Four Rare Cancers
Novartis Seeks Approval for Gleevec in Four Rare Cancers
EAST HANOVER, New JerseyNovartis has submitted supplemental NDAs for imatinib (Gleevec) as treatment for four rare types of cancer. The diseases, all with Gleevec-sensitive pathways, are dermatofibrosarcoma protuberans, certain forms of myeloproliferative disorders, hypereosinophilic syndrome, and systemic mastocytosis.
Articles in this issue
over 19 years ago
Genentech Files sBLA for Avastin for First-Line NSCLC Treatmentover 19 years ago
RFA Effective for Single, Small Hepatocellular Carcinomaover 19 years ago
New Imaging, ChemoRT Recommendations From NCCNover 19 years ago
Panitumumab Improves PFS in Advanced Colon Caover 19 years ago
Studies Question Watchful Waiting for Some Prostate Ca Ptsover 19 years ago
Growing Evidence Supports Stem Cell Hypothesis of Cancerover 19 years ago
FDA Approves New Every-3-Week Dosing for Aranespover 19 years ago
Telephone Often Delivers News of Breast Cancer Diagnosisover 19 years ago
IND Submitted for CYT-500Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































